BA9™, an effective Cytostatic Limus Drug

Rapid 28 day BA9™ transfer to the vessel wall achieved through enhanced high lipophilicity delivering:
  • Greater Local Bioavailability
  • Targeted Drug Release
  • Local tissue warehousing allowing Sustained Tissue Release, with Therapeutic Effect up to 100 days12,13
  • Longer half-life than other commonly used Limus Drugs, approximately 20 days in tissue12,13
  • Potent Neointimal Suppression

Increasing Safety and Efficacy

By leaving a bare metal stent luminal surface, BioFreedom™ promotes rapid reendothelialization, improves the healing process14 and allows for ultra-short 1 month DAPT.


> More details about Biolimus A9™

11521-000-EN - Rev.01 + 11903-000-EN - Rev.01 + 11524-000-EN - Rev.01 + 11881-000-EN - Rev.04
Movie - How does it work?
Watch the working principle of our BA9™
BA9 brochure

12. Tada et al. Circulation: Cardiovascular Interventions. 2010;3:174-183
13. Internal BioFreedom Tissue PK Report
14. Lee, W.L.S. The first establishment of early healing profile and 9-month outcomes of a new polymer-free biolimus A9 drug-coated stent by longitudinal sequential OCT follow-ups: the EGO-BIOFREEDOM study. EuroPCR (2015)

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, Chroma™, BioStream™, BMX-J®, BioPath™, Powerline™, RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT AG. Blue Sail Medical Co., Ltd is the parent company of NVT AG and Biosensors International Group, Ltd. and its affliates are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, Chroma, BioStream, BMX-J, BioPath, Juno, S-Stent, Powerline, Rise NC and Quadrature Link are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. ALLEGRA™ is CE Mark approved (CE 0124). All other cited trademarks are the property of their respective owners.